Barclays
MLTX icon

Barclays’s MoonLake Immunotherapeutics MLTX Stock Holding History

Barclays’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$52.5K Sell
4,490
-7,418
-62% -$121K ﹤0.01% 4555
2026
Q2 		$232K Sell
11,908
-15,694
-57% -$284K ﹤0.01% 3617
2026
Q1 		$515K Sell
27,602
-22,649
-45% -$375K ﹤0.01% 3171
2025
Q4 		$662K Buy
50,251
+50,235
+313,969% +$593K ﹤0.01% 3694
2025
Q3 		$115 Sell
16
-4,537
-100% -$236K ﹤0.01% 5267
2025
Q2 		$215K Sell
4,553
-15,046
-77% -$613K ﹤0.01% 4226
2025
Q1 		$766K Buy
19,599
+14,953
+322% +$644K ﹤0.01% 3268
2024
Q4 		$252K Sell
4,646
-995
-18% -$50.8K ﹤0.01% 4201
2024
Q3 		$284K Buy
5,641
+5,229
+1,269% +$245K ﹤0.01% 4117
2024
Q2 		$18.1K Sell
412
-3,367
-89% -$143K ﹤0.01% 4450
2024
Q1 		$190K Sell
3,779
-2,335
-38% -$127K ﹤0.01% 4142
2023
Q4 		$369K Buy
6,114
+2,802
+85% +$144K ﹤0.01% 4064
2023
Q3 		$189K Buy
+3,312
New +$183K ﹤0.01% 3327
2023
Q1 		– Sell
-55,952
Closed -$587K – 5249
2022
Q4 		$587K Buy
55,952
+40,768
+268% +$363K ﹤0.01% 3206
2022
Q3 		$118K Buy
15,184
+101
+0.7% +$714 ﹤0.01% 3472
2022
Q2 		$79K Buy
+15,083
New +$94.8K ﹤0.01% 3865

Other funds holding MLTX

Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Achmea Investment Management
Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return
BankPlus Wealth Management
BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Savant Capital
Savant Capital Rockford, Illinois $35B AUM 15.18% 1-Year Est. Return

Barclays's MLTX Position: Q3 2026 in Review

Barclays reduced its MoonLake Immunotherapeutics (MLTX) stake by 62% in Q3 2026, selling an estimated $121K and leaving 4,490 shares worth $52.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4555.

Barclays first reported a position in MLTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $766K in Q1 2025. 41 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Barclays held 4,490 shares of MoonLake Immunotherapeutics worth $52.5K as of Q3 2026.
  • Barclays sold 7,418 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $121K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4555 holding.
  • Barclays first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 16 quarters since.
  • Barclays's MoonLake Immunotherapeutics position peaked at $766K in Q1 2025.
  • 41 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.